CG
NVCR icon

Cutler Group’s NovoCure NVCR Stock Holding History

Cutler Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$13K Buy
+869
New +$12.8K ﹤0.01% 1188
2023
Q4 		– Sell
-100
Closed -$1.34K – 4102
2023
Q3 		$1K Sell
100
-1,635
-94% -$47.1K ﹤0.01% 3582
2023
Q2 		$72K Sell
1,735
-1,650
-49% -$102K 0.01% 1104
2023
Q1 		$203K Buy
+3,385
New +$271K 0.02% 671
2022
Q1 		– Sell
-9,760
Closed -$719K – 5798
2021
Q4 		$732K Buy
9,760
+6,460
+196% +$648K 0.03% 574
2021
Q3 		$383K Buy
3,300
+1,600
+94% +$242K 0.02% 935
2021
Q2 		$377K Buy
+1,700
New +$331K 0.02% 906
2020
Q3 		– Sell
-500
Closed -$40K – 5079
2020
Q2 		$29K Sell
500
-850
-63% -$55.9K ﹤0.01% 2122
2020
Q1 		$90K Buy
+1,350
New +$107K ﹤0.01% 1377
2019
Q4 		– Sell
-400
Closed -$29K – 4408
2019
Q3 		$29K Buy
+400
New +$32K ﹤0.01% 1918
2018
Q1 		– Sell
-1,306
Closed -$26K – 4989
2017
Q4 		$26K Sell
1,306
-3,171
-71% -$61.1K ﹤0.01% 2343
2017
Q3 		$88K Buy
+4,477
New +$88K ﹤0.01% 1771
2017
Q2 		– Sell
-1,500
Closed -$19.4K – 6838
2017
Q1 		$12K Sell
1,500
-3,324
-69% -$24K ﹤0.01% 3868
2016
Q4 		$37K Buy
4,824
+3,124
+184% +$25.1K ﹤0.01% 2851
2016
Q3 		$14K Sell
1,700
-500
-23% -$4.56K ﹤0.01% 3808
2016
Q2 		$25K Sell
2,200
-4,100
-65% -$51.3K ﹤0.01% 3114
2016
Q1 		$91K Sell
6,300
-1,134
-15% -$16.3K 0.01% 1701
2015
Q4 		$166K Buy
+7,434
New +$178K 0.01% 1335

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's NVCR Position: Q1 2024 in Review

Cutler Group opened a new position in NovoCure (NVCR) in Q1 2024: 869 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1188 among its holdings. This is a return to the name: Cutler Group previously reported a position in NVCR as recently as Q3 2023.

Cutler Group first reported a position in NVCR in Q4 2015 and has held it in 18 quarters since. The position peaked at $732K in Q4 2021. 237 funds tracked by Wall St. Rank hold NVCR as of Q1 2024.

  • Cutler Group held 869 shares of NovoCure worth $13K as of Q1 2024.
  • NovoCure was a new Cutler Group position in Q1 2024.
  • NovoCure made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1188 holding.
  • Cutler Group first reported a position in NovoCure in Q4 2015 and has held it in 18 quarters since.
  • Cutler Group's NovoCure position peaked at $732K in Q4 2021.
  • 237 funds tracked by Wall St. Rank held NovoCure as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.